Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Oct 30, 2020 • 8:00 AM EDT
Ligand Reports Third Quarter 2020 Financial Results
Oct 23, 2020 • 8:30 AM EDT
Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment
Oct 20, 2020 • 2:05 PM EDT
Ligand Provides Highlights from Today’s Investor Day Event
Oct 30, 2020 • 5:30am PDT
See all events
Oct 20, 2020 • 11:00am - 1:00pm EDT
Sep 14, 2020 • 1:00pm EDT